FDA to review “missing” drug company documents
AUTOR(ES)
Lenzer, Jeanne
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=539828Documentos Relacionados
- FDA needs more sophisticated approach to drug safety
- Cytomegalovirus "missing" capsid protein identified as heat-aggregable product of human cytomegalovirus UL46.
- Documents missing from a 10 year old murder case sent to the BMJ
- FDA to review risks of antidepressants in adults
- Predicting Drug–Drug Interactions: An FDA Perspective